The stock of Stellar Biotechnologies Inc (NASDAQ:SBOT) hit a new 52-week low and has $1.77 target or 12.00% below today’s $2.01 share price. The 9 months bearish chart indicates high risk for the $20.38M company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $1.77 price target is reached, the company will be worth $2.45 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 30,823 shares traded hands. Stellar Biotechnologies Inc (NASDAQ:SBOT) has declined 56.38% since April 1, 2016 and is downtrending. It has underperformed by 57.60% the S&P500.
Analysts await Stellar Biotechnologies Inc (NASDAQ:SBOT) to report earnings on December, 12. They expect $-0.14 earnings per share, up 26.32% or $0.05 from last year’s $-0.19 per share. After $-0.14 actual earnings per share reported by Stellar Biotechnologies Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
According to Zacks Investment Research, “Stellar Biotechnologies, Inc. is engaged in the development, manufacture and commercialization of keyhole limpet hemocyanin and technologies. The Company’s principle products consist of: stellar KLH protein and stellar KLH ELISA Kits. KLH is a component for cancer vaccines and anticipated therapeutic vaccines, including those for lymphoma, sarcoma, small cell lung cancer, Alzheimer’s disease, rheumatoid arthritis, lupus and Post Traumatic Stress Disorder chemical dependencies. It operates primarily in the United States, Europe, and Asia. Stellar Biotechnologies, Inc. is headquartered in Port Hueneme, California.”
More news for Stellar Biotechnologies Inc (NASDAQ:SBOT) were recently published by: Marketwatch.com, which released: “Stellar Biotechnologies stock price target cut to $7 from $17 at Maxim Group” on November 05, 2015. Seekingalpha.com‘s article titled: “Stellar Biotechnologies: Vaccine Tech Buoyed By Partnerships” and published on June 23, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.